{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:16:21Z","timestamp":1793654181168,"version":"4.5.1"},"reference-count":92,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"unspecified","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Harvard Pilgrim Health Care Institute"},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSGI-20-030-01-CPPB"],"award-info":[{"award-number":["RSGI-20-030-01-CPPB"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Thomas O. Pyle Fellowship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["bmjmed"],"accepted":{"date-parts":[[2025,10,24]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the survival gains and additional Medicare spending associated with early access to new cancer drugs granted accelerated approval by the US Food and Drug Administration (FDA), compared with access to cancer drugs following completion of confirmatory trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective observational study and economic evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>US Medicare programme, which provides health insurance for adults aged 65 years and older.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Medicare beneficiaries who received new cancer drug indications from the time of FDA accelerated approval to conversion to regular approval, withdrawal from the market, or 31 December 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Use of cancer drugs for indications that initially received FDA accelerated approval between 1 January 2012 and 31 December 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcomes and measures<\/jats:title>\n                    <jats:p>Primary outcomes were life year gains and additional Medicare spending associated with cancer drug indications that initially received FDA accelerated approval. Each indications\u2019s overall survival benefit to patients, if present, was determined, and a partitioned survival model was developed to estimate the life year gains and incremental Medicare spending attributable to early drug access. Beneficiaries who received accelerated approval indications were followed for survival and spending outcomes until 31 December 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>An estimated 178\u2009708 Medicare beneficiaries received access to 90 new cancer drug indications from the time of accelerated approval to conversion to regular approval, withdrawal from the market, or 31 December 2020. Seventeen per cent of beneficiaries (n=30\u2009374) received drugs for indications that were ultimately withdrawn, 5574 (3.1%) received drugs for indications that remained under accelerated approval, and 142\u2009760 (79.9%) received drugs for indications that were subsequently converted to regular approval. Overall, 80\u2009885 (45.3%) beneficiaries received drugs for indications that provided an overall survival benefit to patients. Between 2012 and 2022, use of these drug indications was associated with an estimated 76\u2009164 life years gained. Only three accelerated approvals (nivolumab to treat melanoma, pembrolizumab to treat non-small cell lung cancer, and pemetrexed to treat non-small cell lung cancer) accounted for 68.4% (n=52\u2009107 years) of the total life year gains. The estimated additional cost of early access to these drugs to Medicare was $20.1bn (\u00a315.4bn; \u20ac17.4bn) corresponding to a mean spending of $263 371 (95% confidence interval $180 139 to $373 884) per life year gained. Additional mean Medicare spending per life year gained ranged from $25 947 ($18 174 to $39 829) for melanoma indications to $4.5m ($3.1m to $12.2m) for breast cancer indications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study examined the trade-off between the benefits of earlier access to cancer drugs through the FDA's accelerated approval pathway and the uncertainty surrounding their clinical efficacy at the time of market entry. Accelerated approval yielded uneven survival returns, with a small number of drugs accounting for the majority of life year gains. Medicare incurred substantial costs for treatments that, in over half of cases, did not provide an overall survival benefit to patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjmed-2025-001934","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:25:16Z","timestamp":1765952716000},"page":"e001934","source":"Crossref","is-referenced-by-count":4,"title":["Costs and benefits of early access to new cancer drugs through the US Food and Drug Administration\u2019s accelerated approval pathway: retrospective observational study and economic evaluation"],"prefix":"10.1136","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7192-5751","authenticated-orcid":false,"given":"Huseyin","family":"Naci","sequence":"first","affiliation":[{"name":"Pharmaceutical Policy Lab, London, UK"},{"name":"Department of Health Policy, London School of Economics and Political Science, London, UK"},{"name":"Division of Health Policy and Insurance Research, Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7170-7228","authenticated-orcid":false,"given":"Mahnum","family":"Shahzad","sequence":"additional","affiliation":[{"name":"Pharmaceutical Policy Lab, London, UK"},{"name":"Division of Health Policy and Insurance Research, Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8864-1416","authenticated-orcid":false,"given":"Peter","family":"Murphy","sequence":"additional","affiliation":[{"name":"Pharmaceutical Policy Lab, London, UK"},{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pharmaceutical Policy Lab, London, UK"},{"name":"Department of Pharmacy Administration and Clinical Pharmacy, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Costa","sequence":"additional","affiliation":[{"name":"Division of Health Policy and Insurance Research, Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9218-3320","authenticated-orcid":false,"given":"Joseph S","family":"Ross","sequence":"additional","affiliation":[{"name":"Internal Medicine, Yale School of Medicine, New Haven, CT, USA"},{"name":"Yale Collaboration for Regulatory Rigor Integrity and Transparency, New Haven, CT, USA"},{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA"},{"name":"Yale School of Medicine Center for Outcomes Research & Evaluation, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1069-6668","authenticated-orcid":false,"given":"Anita K","family":"Wagner","sequence":"additional","affiliation":[{"name":"Pharmaceutical Policy Lab, London, UK"},{"name":"Division of Health Policy and Insurance Research, Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"2025121622251260000_4.1.e001934.1","unstructured":"CFR - code of federal regulations title 21. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?CFRPart=314&showFR=1&subpartNode=21:5.0.1.1.4.8 [Accessed 16 Oct 2024]."},{"key":"2025121622251260000_4.1.e001934.2","unstructured":"21 CFR Part 314 Subpart H -- Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses. Available: https:\/\/www.ecfr.gov\/current\/title-21\/part-314\/subpart-H [Accessed 16 Oct 2024]."},{"key":"2025121622251260000_4.1.e001934.3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.31753","article-title":"Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel Therapeutics","volume":"6","author":"Wong","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025121622251260000_4.1.e001934.4","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.24.1.67"},{"key":"2025121622251260000_4.1.e001934.5","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1001\/jama.2024.4175","article-title":"Associations Between Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments","volume":"331","author":"Wallach","year":"2024","journal-title":"JAMA"},{"key":"2025121622251260000_4.1.e001934.6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.24406","article-title":"Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016","volume":"3","author":"Ladanie","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025121622251260000_4.1.e001934.7","doi-asserted-by":"publisher","DOI":"10.1111\/1468-0009.12261"},{"key":"2025121622251260000_4.1.e001934.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.282034"},{"key":"2025121622251260000_4.1.e001934.9","doi-asserted-by":"publisher","DOI":"10.1111\/1468-0009.12413"},{"key":"2025121622251260000_4.1.e001934.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1705800"},{"key":"2025121622251260000_4.1.e001934.11","unstructured":"US Government Accountability Office . Drug safety: fda expedites many applications, but data for postapproval oversight need improvement. US GAO. Available: https:\/\/www.gao.gov\/products\/gao-16-192 [Accessed 16 Oct 2024]."},{"key":"2025121622251260000_4.1.e001934.12","unstructured":"US Department of Health and Human Services . Delays in Confirmatory Trials for Drug Applications Granted FDA\u2019s Accelerated Approval Raise Concerns. 2022. Available: https:\/\/oig.hhs.gov\/reports\/all\/2022\/delays-in-confirmatory-trials-for-drug-applications-granted-fdas-accelerated-approval-raise-concerns\/ [accessed 5 Dec 2025]"},{"key":"2025121622251260000_4.1.e001934.13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n1898","article-title":"FDA allows drugs without proven clinical benefit to languish for years on accelerated pathway","volume":"374","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"2025121622251260000_4.1.e001934.14","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.0217","article-title":"Timing of Confirmatory Trials for Drugs Granted Accelerated Approval Based on Surrogate Measures From 2012 to 2021","volume":"4","author":"Deshmukh","year":"2023","journal-title":"JAMA Health Forum"},{"key":"2025121622251260000_4.1.e001934.15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.9415"},{"key":"2025121622251260000_4.1.e001934.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n1959","article-title":"Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study","volume":"374","author":"Gyawali","year":"2021","journal-title":"BMJ"},{"key":"2025121622251260000_4.1.e001934.17","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2025121622251260000_4.1.e001934.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.11.012"},{"key":"2025121622251260000_4.1.e001934.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4107"},{"key":"2025121622251260000_4.1.e001934.20","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/jamainternmed.2018.4710","article-title":"Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic Review and Quantitative Analysis","volume":"178","author":"Kovic","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2025121622251260000_4.1.e001934.21","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jamainternmed.2015.5868","article-title":"Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals","volume":"175","author":"Kim","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2025121622251260000_4.1.e001934.22","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","article-title":"Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval","volume":"179","author":"Gyawali","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2025121622251260000_4.1.e001934.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.2396"},{"key":"2025121622251260000_4.1.e001934.24","doi-asserted-by":"publisher","DOI":"10.1177\/1740774518770648"},{"key":"2025121622251260000_4.1.e001934.25","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","article-title":"A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review","volume":"4","author":"Beaver","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025121622251260000_4.1.e001934.26","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr062"},{"key":"2025121622251260000_4.1.e001934.27","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3977"},{"key":"2025121622251260000_4.1.e001934.28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1001\/jamaoncol.2022.7770","article-title":"Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval","volume":"9","author":"Parikh","year":"2023","journal-title":"JAMA Oncol"},{"key":"2025121622251260000_4.1.e001934.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1700446"},{"key":"2025121622251260000_4.1.e001934.30","unstructured":"An overview of medicare. KFF; 2019. Available: https:\/\/www.kff.org\/medicare\/issue-brief\/an-overview-of-medicare\/ [Accessed 8 Jul 2025]."},{"key":"2025121622251260000_4.1.e001934.31","unstructured":"Cancer of any site - cancer stat facts. SEER. Available: https:\/\/seer.cancer.gov\/statfacts\/html\/all.html [Accessed 2 Dec 2024]."},{"key":"2025121622251260000_4.1.e001934.32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.21468","article-title":"Evaluation of Trends in Oncology Drug Spending in Medicare, 2016 to 2020","volume":"5","author":"Kyle","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025121622251260000_4.1.e001934.33","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.3937","article-title":"Medicare Spending on Drugs With Accelerated Approval, 2015-2019","volume":"2","author":"Rome","year":"2021","journal-title":"JAMA Health Forum"},{"key":"2025121622251260000_4.1.e001934.34","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-067975","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"376","author":"Husereau","year":"2022","journal-title":"BMJ"},{"key":"2025121622251260000_4.1.e001934.35","unstructured":"Medicare part D drug spending dashboard. CMS Data. Available: https:\/\/data.cms.gov\/tools\/medicare-part-d-drug-spending-dashboard [Accessed 21 Jul 2025]."},{"key":"2025121622251260000_4.1.e001934.36","unstructured":"Medicare part B drug spending dashboard. CMS Data. Available: https:\/\/data.cms.gov\/tools\/medicare-part-b-drug-spending-dashboard [Accessed 21 Jul 2025]."},{"key":"2025121622251260000_4.1.e001934.37","doi-asserted-by":"crossref","first-page":"938","DOI":"10.7326\/M21-4442","article-title":"Medicare Spending on Drugs With Accelerated Approval","volume":"175","author":"Ballreich","year":"2022","journal-title":"Ann Intern Med"},{"key":"2025121622251260000_4.1.e001934.38","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/jamainternmed.2021.5989","article-title":"Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated Approval","volume":"181","author":"Shahzad","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2025121622251260000_4.1.e001934.39","unstructured":"Ochieng N , Cubanski J . A snapshot of sources of coverage among medicare beneficiaries. KFF; 2024. Available: https:\/\/www.kff.org\/medicare\/issue-brief\/a-snapshot-of-sources-of-coverage-among-medicare-beneficiaries\/ [Accessed 21 Jul 2025]."},{"key":"2025121622251260000_4.1.e001934.40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1162\/ajhe_a_00001","article-title":"HOW MUCH FAVORABLE SELECTION IS LEFT IN MEDICARE ADVANTAGE?","volume":"1","author":"Newhouse","year":"2015","journal-title":"Am J Health Econ"},{"key":"2025121622251260000_4.1.e001934.41","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.4001","article-title":"Health Care Utilization and Spending in Medicare Advantage vs Traditional Medicare","volume":"2","author":"Schwartz","year":"2021","journal-title":"JAMA Health Forum"},{"key":"2025121622251260000_4.1.e001934.42","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1001\/jamainternmed.2021.3505","article-title":"Communication of Survival Data in US Food and Drug Administration\u2013Approved Labeling of Cancer Drugs","volume":"181","author":"Naci","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2025121622251260000_4.1.e001934.43","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00152-9"},{"key":"2025121622251260000_4.1.e001934.44","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.1158","article-title":"Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017","volume":"3","author":"Skydel","year":"2022","journal-title":"JAMA Health Forum"},{"key":"2025121622251260000_4.1.e001934.45","unstructured":"How BLS Measures Price Change for Medical Care Services in the Consumer Price Index. Bureau of Labor Statistics. Available: https:\/\/www.bls.gov\/cpi\/factsheets\/medical-care.htm [Accessed 14 Mar 2025]."},{"key":"2025121622251260000_4.1.e001934.46","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/0272989X16670617","article-title":"Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling","volume":"37","author":"Williams","year":"2017","journal-title":"Med Decis Making"},{"key":"2025121622251260000_4.1.e001934.47","unstructured":"Woods B , Sideris E , Palmer S , et al . NICE DSU technical support document 19: Partitioned survival analysis for decision modelling in health care: a critical review. Report by the Decision Support Unit.."},{"key":"2025121622251260000_4.1.e001934.48","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","article-title":"Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now","volume":"23","author":"Woods","year":"2020","journal-title":"Value Health"},{"key":"2025121622251260000_4.1.e001934.49","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X13497998"},{"key":"2025121622251260000_4.1.e001934.50","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12472398"},{"key":"2025121622251260000_4.1.e001934.51","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1017\/S0266462319000175","article-title":"How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017","volume":"35","author":"Gallacher","year":"2019","journal-title":"Int J Technol Assess Health Care"},{"key":"2025121622251260000_4.1.e001934.52","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X19881967"},{"key":"2025121622251260000_4.1.e001934.53","unstructured":"Value assessment framework. ICER. Available: https:\/\/icer.org\/our-approach\/methods-process\/value-assessment-framework\/ [Accessed 21 Jul 2025]."},{"key":"2025121622251260000_4.1.e001934.54","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1392"},{"key":"2025121622251260000_4.1.e001934.55","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.33601","article-title":"Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018","volume":"4","author":"Wallach","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025121622251260000_4.1.e001934.56","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh279"},{"key":"2025121622251260000_4.1.e001934.57","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/jamaoncol.2015.0203","article-title":"Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer","volume":"1","author":"Lakdawalla","year":"2015","journal-title":"JAMA Oncol"},{"key":"2025121622251260000_4.1.e001934.58","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S1470-2045(24)00596-5","article-title":"Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment","volume":"25","author":"Forrest","year":"2024","journal-title":"Lancet Oncol"},{"key":"2025121622251260000_4.1.e001934.59","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jamaoncol.2016.3337","article-title":"The Trade-off Between Speed and Safety in Drug Approvals","volume":"3","author":"Jena","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025121622251260000_4.1.e001934.60","unstructured":"US Food and Drug Administration . Accelerated approval and considerations for determining whether a confirmatory trial is underway. 2025. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/accelerated-approval-and-considerations-determining-whether-confirmatory-trial-underway [Accessed 13 Mar 2025]."},{"key":"2025121622251260000_4.1.e001934.61","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1056\/NEJMp2208954","article-title":"The On- and Off-Ramps of Oncology Accelerated Approval","volume":"387","author":"Fashoyin-Aje","year":"2022","journal-title":"N Engl J Med"},{"key":"2025121622251260000_4.1.e001934.62","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jama.2023.0625","article-title":"Association Between Preapproval Confirmatory Trial Initiation and Conversion to Traditional Approval or Withdrawal in the FDA Accelerated Approval Pathway","volume":"329","author":"Shahzad","year":"2023","journal-title":"JAMA"},{"key":"2025121622251260000_4.1.e001934.63","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n2191","article-title":"Raising the bar for using surrogate endpoints in drug regulation and health technology assessment","volume":"374","author":"Dawoud","year":"2021","journal-title":"BMJ"},{"key":"2025121622251260000_4.1.e001934.64","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6776"},{"key":"2025121622251260000_4.1.e001934.65","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.33667","article-title":"Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval","volume":"4","author":"Wallach","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025121622251260000_4.1.e001934.66","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.36230","article-title":"Treatment Effects in Randomized and Nonrandomized Studies of Pharmacological Interventions: A Meta-Analysis","volume":"7","author":"Salcher-Konrad","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2025121622251260000_4.1.e001934.67","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/phar.2789","article-title":"Accelerated approval drug labels often lack information for clinical decision\u2010making","volume":"43","author":"Ballreich","year":"2023","journal-title":"Pharmacotherapy"},{"key":"2025121622251260000_4.1.e001934.68","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2217\/cer-2021-0184","article-title":"Potential policy reforms to strengthen the accelerated approval pathway","volume":"10","author":"Kaltenboeck","year":"2021","journal-title":"J Comp Eff Res"},{"key":"2025121622251260000_4.1.e001934.69","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30415-1"},{"key":"2025121622251260000_4.1.e001934.70","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1377\/hlthaff.2022.00119","article-title":"Accelerated Approval Of Cancer Drugs: No Economic Reward For Drug Makers That Conduct Confirmatory Trials","volume":"41","author":"Frank","year":"2022","journal-title":"Health Aff (Millwood)"},{"key":"2025121622251260000_4.1.e001934.71","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/1468-0009.12670","article-title":"Improving Food and Drug Administration\u2013Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated Approval","volume":"101","author":"Neumann","year":"2023","journal-title":"Milbank Q"},{"key":"2025121622251260000_4.1.e001934.72","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1001\/jama.2021.18308","article-title":"Paying for Cancer Drugs That Prove Their Benefit","volume":"326","author":"Frank","year":"2021","journal-title":"JAMA"},{"key":"2025121622251260000_4.1.e001934.73","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2023-000802","article-title":"Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study","volume":"3","author":"Mooghali","year":"2024","journal-title":"bmjmed"},{"key":"2025121622251260000_4.1.e001934.74","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.20726","article-title":"Prescribing Changes After Accelerated vs Regular Approval of Oncology Therapies","volume":"8","author":"Parikh","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2025121622251260000_4.1.e001934.75","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.43285","article-title":"National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval","volume":"6","author":"Cliff","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025121622251260000_4.1.e001934.76","article-title":"Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001-2020","volume":"45","author":"Wei","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"2025121622251260000_4.1.e001934.77","article-title":"Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis","volume":"22","author":"Ivama-Brummell","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"2025121622251260000_4.1.e001934.78","doi-asserted-by":"publisher","DOI":"10.1111\/1468-0009.12476"},{"key":"2025121622251260000_4.1.e001934.79","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamainternmed.2020.8441","article-title":"Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval","volume":"181","author":"Cherla","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2025121622251260000_4.1.e001934.80","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1016\/S1470-2045(23)00357-1","article-title":"Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?","volume":"24","author":"Cramer","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025121622251260000_4.1.e001934.81","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1215\/03616878-10041107","article-title":"Medicaid and Accelerated Approval: Spending on Drugs with and without Proven Clinical Benefits","volume":"47","author":"Sachs","year":"2022","journal-title":"J Health Polit Policy Law"},{"key":"2025121622251260000_4.1.e001934.82","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.3177","article-title":"Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval","volume":"2","author":"Sachs","year":"2021","journal-title":"JAMA Health Forum"},{"key":"2025121622251260000_4.1.e001934.83","doi-asserted-by":"crossref","first-page":"382","DOI":"10.6004\/jnccn.2024.7010","article-title":"Life Years Gained From the FDA Accelerated Approval Program in Oncology: A Portfolio Model","volume":"22","author":"Benedict","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"2025121622251260000_4.1.e001934.84","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01074"},{"key":"2025121622251260000_4.1.e001934.85","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1377\/hlthaff.2020.02149","article-title":"Comparing Medicare Advantage And Traditional Medicare: A Systematic Review","volume":"40","author":"Agarwal","year":"2021","journal-title":"Health Aff (Millwood)"},{"key":"2025121622251260000_4.1.e001934.86","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2024.4868","article-title":"High-Cost Cancer Drug Use in Medicare Advantage and Traditional Medicare","volume":"6","author":"Bradley","year":"2025","journal-title":"JAMA Health Forum"},{"key":"2025121622251260000_4.1.e001934.87","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2021-000094","article-title":"Extrapolation beyond the end of trials to estimate long term survival and cost effectiveness","volume":"1","author":"Latimer","year":"2022","journal-title":"bmjmed"},{"key":"2025121622251260000_4.1.e001934.88","unstructured":"Latimer N . 2. NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data. Report by the Decision Support Unit; 2011.20."},{"key":"2025121622251260000_4.1.e001934.89","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamainternmed.2016.7761","article-title":"Quality of Life, Overall Survival, and Costs of Cancer Drugs Approved Based on Surrogate Endpoints","volume":"177","author":"Rupp","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2025121622251260000_4.1.e001934.90","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/ijc.34473","article-title":"The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020","volume":"152","author":"Gloy","year":"2023","journal-title":"Int J Cancer"},{"key":"2025121622251260000_4.1.e001934.91","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamaoncol.2019.3994","article-title":"Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia: A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare Beneficiaries","volume":"6","author":"Bird","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025121622251260000_4.1.e001934.92","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1200\/JCO.2017.72.3742","article-title":"Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries","volume":"35","author":"Shih","year":"2017","journal-title":"JCO"}],"container-title":["BMJ Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjmed-2025-001934","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:25:26Z","timestamp":1765952726000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjmedicine.bmj.com\/lookup\/doi\/10.1136\/bmjmed-2025-001934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":92,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,16]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjmed-2025-001934"],"URL":"https:\/\/doi.org\/10.1136\/bmjmed-2025-001934","relation":{},"ISSN":["2754-0413"],"issn-type":[{"value":"2754-0413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}